

## ASX ANNOUNCEMENT

ASX Market Announcements  
Australian Securities Exchange Limited  
10<sup>th</sup> Floor, 20 Bond Street  
SYDNEY NSW 2000

### Admedus Limited (ASX:AHZ)

#### REGULATORY APPROVAL GRANTED IN CANADA FOR CARDIOCEL 3D® AND VASCUCEL®

Admedus Limited (ASX:AHZ) announces that it has received regulatory approval to introduce its products, CardioCel 3D® and VascuCel®, in Canada, alongside flagship product CardioCel® which is already available.

CardioCel 3D® is the latest product from Admedus' proprietary ADAPT® portfolio and was officially launched in the United States on 1 February 2018.

CardioCel 3D® represents a disruptive technology in the high-complexity congenital defect repair space. Offering patients, the long-term health benefits of our clinically-superior ADAPT® technology. It's unique pre-shaped curve provides physicians immediate access to a clinically-superior, off-the-shelf, optimised arch reconstruction solution with non-antigenic response and unique calcification resistance.

Canada is the second market to have access to this cutting-edge technology and the first executed stage of the Company's expansion strategy for the shaped-tissue franchise. CardioCel 3D® and VascuCel® will be sold in Canada through Admedus' usual distribution network.

CEO Wayne Paterson said,

"We welcome today's announcement and are pleased to be able to expand our product offering in Canada, giving physicians and patients access to the numerous health benefits of our latest clinically-superior technology."

"This opportunity presents Admedus with a valuable opportunity to move up the value chain and increase our presence and market share in North America."

**ENDS**

**Admedus Limited**  
ABN 35 088 221 078

**Registered Office**  
Level 9  
301 Coronation Drive  
Milton QLD 4064

**Customer Service**  
T 1300 550 310  
F 1300 880 398

**International**  
T: +61 8 9266 0100  
F: +61 8 9266 0199

E: [info@admedus.com](mailto:info@admedus.com)  
W: [www.admedus.com](http://www.admedus.com)

**Brisbane • Minneapolis**  
**Zurich • Singapore**

**Background:****ADAPT®**

ADAPT® treated tissue has been scientifically proven to more closely mimic the characteristics of normal human tissue which promotes a more tolerant immune response and improved tissue ingrowth. Our clinically superior ADAPT® tissue products are the only one of their kind to have achieved nine years without calcification or degradation. With the potential for a product lifespan free from calcification, physicians can potentially intervene across a broader age spectrum and provide their patients with a solution for life.

**About Admedus Limited**

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Website: [www.admedus.com](http://www.admedus.com)

Facebook: [www.facebook.com/Admedus](http://www.facebook.com/Admedus)

Twitter: @Admedus

*For more information, please contact:*

Admedus Limited

Barbara Ferres

+61 7 3152 3216

communications@admedus.com

**Admedus Limited**  
ABN 35 088 221 078

**Registered Office**  
Level 9  
301 Coronation Drive  
Milton QLD 4064

**Customer Service**  
T 1300 550 310  
F 1300 880 398

**International**  
T: +61 8 9266 0100  
F: +61 8 9266 0199

E: info@admedus.com  
W: www.admedus.com

**Brisbane • Minneapolis**  
**Zurich • Singapore**